MedPath

Evaluation of Biomarkers of Traumatic Brain Injury

Completed
Conditions
Traumatic Brain Injury
Registration Number
NCT01426919
Lead Sponsor
Banyan Biomarkers, Inc
Brief Summary

The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other clinical information within 12 hours of injury to assist in determining the need for a CT scan of the head.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2011
Inclusion Criteria
  • subject is at least 18 years of age at screening
  • suspected traumatically induced head injury as a result of insult to the head from external force
  • GCS 9-15 at time of informed consent
  • workup includes head CT scan as part of clinical emergency care within 3 hours of presenting and within 12 hours of injury
  • blood sample collected within 3 hours of presenting and within 12 hours of injury
  • subject or legal representative is willing to undergo informed consent
Exclusion Criteria
  • participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study acceptable)
  • time of injury cannot be determined
  • primary diagnosis of ischemic or hemorrhagic stroke
  • venipuncture not feasible
  • a condition precluding entry into the CT scanner
  • subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, and history of neurosurgery, stroke or TIA within the last 30 days
  • administration of blood transfusion after head injury and prior to study blood draw
  • subject is otherwise determined by the Investigator to be unsuitable for participation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation of assay result with absence of acute intracranial lesionsDay 1
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (24)

University of California San Diego

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

Hartford Hospital

πŸ‡ΊπŸ‡Έ

Hartford, Connecticut, United States

University of Florida

πŸ‡ΊπŸ‡Έ

Gainesville, Florida, United States

Tallahassee Neurological Clinic

πŸ‡ΊπŸ‡Έ

Tallahassee, Florida, United States

University of Massachusetts Medical School

πŸ‡ΊπŸ‡Έ

Worcester, Massachusetts, United States

Wayne State University - Detroit Receiving Hospital

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

Wayne State University - Sinai Grace Hospital

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

Washington University

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

University of Rochester Medical Center

πŸ‡ΊπŸ‡Έ

Rochester, New York, United States

University of North Carolina at Chapel Hill

πŸ‡ΊπŸ‡Έ

Chapel Hill, North Carolina, United States

Scroll for more (14 remaining)
University of California San Diego
πŸ‡ΊπŸ‡ΈSan Diego, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.